TGFßtrap/TIGIT / Compass Therap - LARVOL DELTA

TIGIT Remains a Tempting Target for Immunotherapy Combinations, Despite Setbacks (OncLive) - "The exploration of TIGIT is part of the next steps in cancer immunotherapy aimed at overcoming therapeutic resistance that can take hold because of numerous factors that modulate the immune response, according to Jedd D. Wolchok, MD, PhD, FASCO....During the ASCO Plenary Series program, Melissa L. Johnson, MD, presented interim efficacy findings from ARC-7....'There have been mixed signals from prior studies looking at TIGIT targeting. The promising results of the combination immunotherapy treatment in this study support further investigation, and if confirmed, could lead to a new standard of care for patients with advanced lung cancer,' Lauren A. Byers, MD..."

Media quote